SCHEMBL3258353

SCHEMBL3258353

O=C(Nc1ccccn1)N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.60
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
PKM P14618 2/20 0.58
FAAH O00519 4/20 0.56
GAA P10253 2/20 0.54
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16585513 0.98 TRPV1 (0.59) TRPV1NPC1RAB9APKMFAAH
SCHEMBL9378280 0.87 TRPV1 (0.57) TRPV1NPC1RAB9APKMFAAH
SCHEMBL3954599 0.86 POLB (0.59) TRPV1NPC1RAB9APKMFAAH
SCHEMBL17187727 0.86 CYP2C9 (0.60) TRPV1NPC1RAB9APKMFAAH
SCHEMBL27165159 0.84 TRPV1 (0.55) TRPV1NPC1RAB9APKMFAAH
SCHEMBL471106 0.83 LMNA (0.57) TRPV1NPC1RAB9APKMFAAH
SCHEMBL28367233 0.81 NPC1 (0.56) TRPV1NPC1RAB9APKMFAAH
SCHEMBL17667058 0.79 DHODH (0.51) NPC1RAB9APKMGAAALDH1A1
SCHEMBL10858722 0.79 RAB9A (0.54) NPC1RAB9APKMGAAMEN1
SCHEMBL17667055 0.79 DHODH (0.51) NPC1RAB9APKMGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3719012-B1 N-[4-[(2-AMINO-4-PYRIDINYL)OXY]-3-FLUOROPHENYL]-3-(4-FLUOROPHENYL)-1,2,3,4-TETRAHYDRO-2,4-DIOXO-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AS C-MET/AXL INHIBITORS FOR THE TREATMENT OF TUMORS MEDSHINE DISCOVERY INC (CN) 2024-03-06 EP disclosed
US-20100063278-A1 N-Formyl Hydroxylamines compounds NOVARTIS AG (CH) 2010-03-11 US disclosed
US-7615635-B2 N-formyl hydroxylamines NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20090062537-A1 N-Formyl Hydrozyamine Compounds LEE KWANGHO 2009-03-05 US disclosed
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics VICURON HOLDINGS LLC 2008-07-03 US disclosed
EP-1896452-A2 N-FORMYL HYDROXYLAMINE COMPOUNDS Novartis Pharma AG. (CH) 2008-03-12 EP disclosed
WO-2006127576-A2 N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS NOVARTIS AG (CH) 2006-11-30 WO disclosed
EP-0898569-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GmbH (DE) 1999-03-03 EP disclosed
WO-1997040038-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GMBH (DE) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063278-A1 N-Formyl Hydroxylamines compounds PDF, MMP2, HNMT TRPV1 1763/4885NPC1 2825/4885RAB9A 2439/4885
US-20090062537-A1 N-Formyl Hydrozyamine Compounds PDF, HNMT, MMP2 TRPV1 2042/4885NPC1 2898/4885RAB9A 797/4885
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics PDF, MMP2, PEPD TRPV1 3840/4885NPC1 3404/4885RAB9A 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.